North America Hospital Acquired Infections Therapeutic Market Size & Outlook
North America hospital acquired infections therapeutic market, 2018-2030 (US$M)
Related Markets
North America hospital acquired infections therapeutic market highlights
- The North America hospital acquired infections therapeutic market generated a revenue of USD 1,206.8 million in 2023.
- The market is expected to grow at a CAGR of 6% from 2024 to 2030.
- In terms of segment, urinary tract infections was the largest revenue generating application in 2023.
- Urinary Tract Infections is the most lucrative application segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 1,206.8 million |
| Market revenue in 2030 | USD 1,818.1 million |
| Growth rate | 6% (CAGR from 2023 to 2030) |
| Largest segment | Urinary tract infections |
| Fastest growing segment | Urinary Tract Infections |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Urinary Tract Infections |
| Key market players worldwide | Merck & Co Inc, Pfizer Inc, Bayer AG, GlaxoSmithKline, Daiichi Sankyo Co Ltd, AbbVie Inc, Abbott Laboratories, Roche, Allergan |
Other key industry trends
- In terms of revenue, North America region accounted for 27.5% of the global hospital acquired infections therapeutic market in 2023.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,787.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hospital Acquired Infections Therapeutic Market Scope
Hospital Acquired Infections Therapeutic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America hospital acquired infections therapeutic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hospital acquired infections therapeutic market will help companies and investors design strategic landscapes.
Urinary tract infections was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America hospital acquired infections therapeutic market based on urinary tract infections covering the revenue growth of each sub-segment from 2018 to 2030.
- North America Hospital Acquired Infections Therapeutic Application Outlook (Revenue, USD Million, 2018-2030)
- Urinary Tract Infections
- Ventilator Associated Pneumonia
- Surgical Site Infections
- Bloodstream Infections
- Other Hospital Infections (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
- North America Hospital Acquired Infections Therapeutic Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Antibacterial Drugs
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- Others
- Antiviral Drugs
- Antifungal Drugs
- Antibacterial Drugs
Reasons to subscribe to North America hospital acquired infections therapeutic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America hospital acquired infections therapeutic market databook
-
Our clientele includes a mix of hospital acquired infections therapeutic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America hospital acquired infections therapeutic market, including forecasts for subscribers. This continent databook contains high-level insights into North America hospital acquired infections therapeutic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America hospital acquired infections therapeutic market
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
